The oral Janus kinase (JAK) inhibitor, upadacitinib, is emerging as a potential new treatment option for patients with ankylosing spondylitis (AS) according to results from a phase 2/3 study. The drug, which is not yet available in Australia, is approved in the US and Europe to treat rheumatoid arthritis (RA) but has recently been explored ...
JAK inhibitors the ‘new therapeutic paradigm’ in ankylosing spondylitis
By Sunalie Silva
19 Nov 2019